产品
编 号：F430766
分子式：C22H26N4O3
分子量：394.47
分子式：C22H26N4O3
分子量：394.47
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 701232-20-4
产品详情
生物活性：
T863 is an orally active, selective and potent DGAT1 (acyl-CoA:diacylglycerol acyltransferase 1) inhibitor with an IC50 of 15 nM. T863 has no inhibitory activity against human MGAT3, human DGAT2, or human MGAT2. T863 interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.
体内研究：
T863（30 mg/kg；口服）可导致体重减轻、血清和肝脏甘油三酯降低，并改善胰岛素敏感性。Animal Model:C57BL6 normal mice (8 weeks old) or diet-induced obese (DIO) mice (10 months old, fed a high fat diet for 8 months)
Dosage:30 mg/kg (5 μL/g)
Administration:Oral administration; once a day for days 1-7 and twice a day for days 8-14
Result:Significantly delayed fat absorption and resulted in lipid accumulation in the distal small intestine of mice, mimicking the effects of genetic ablation of DGAT1.
体外研究：
T863（持续 3 天）增强胰岛素刺激的葡萄糖摄取，表明脂肪细胞可能在分化的 3T3-L1 脂肪细胞中抑制 DGAT1 后提高胰岛素敏感性。
T863 is an orally active, selective and potent DGAT1 (acyl-CoA:diacylglycerol acyltransferase 1) inhibitor with an IC50 of 15 nM. T863 has no inhibitory activity against human MGAT3, human DGAT2, or human MGAT2. T863 interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.
体内研究：
T863（30 mg/kg；口服）可导致体重减轻、血清和肝脏甘油三酯降低，并改善胰岛素敏感性。Animal Model:C57BL6 normal mice (8 weeks old) or diet-induced obese (DIO) mice (10 months old, fed a high fat diet for 8 months)
Dosage:30 mg/kg (5 μL/g)
Administration:Oral administration; once a day for days 1-7 and twice a day for days 8-14
Result:Significantly delayed fat absorption and resulted in lipid accumulation in the distal small intestine of mice, mimicking the effects of genetic ablation of DGAT1.
体外研究：
T863（持续 3 天）增强胰岛素刺激的葡萄糖摄取，表明脂肪细胞可能在分化的 3T3-L1 脂肪细胞中抑制 DGAT1 后提高胰岛素敏感性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备